

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

## EQA round: BIL2/20 - Bilirubin Neonatal

Deadline: 21.08.2020

|  |  |  |
|--|--|--|
| RoM = robust average                                 | AV = assigned value  | Dmax = acceptable percent difference     |
| SD = standard deviation                              | CRV = certified reference value                                      | LL = lower limit                         |
| CV = coefficient of variation                        | RV = reference value   | UL = upper limit                         |
| Ntot = total number of the participants              | CVE = consensus value from experts                                   | Neva = number of evaluated participants  |
| Nout = number of results excluded before calculation | CVP = consensus value from all participants                          | Nsuc = number of successful participants |
|  | CVPG = consensus value from participants groups                      | Srel = success (relative)                |
|  | U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2) |  |

| Test                            | [unit]   | Comparability |    |        |                  |                  |                  |                 |                  |     |     |                  |                  |                  |
|---------------------------------|----------|---------------|----|--------|------------------|------------------|------------------|-----------------|------------------|-----|-----|------------------|------------------|------------------|
|                                 |          | RoM           | SD | CV [%] | N <sub>tot</sub> | N <sub>out</sub> | AV               | U <sub>AV</sub> | D <sub>max</sub> | LL  | UL  | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> |
| <b>(215) Bilirubin total</b>    |          |               |    |        | 140              |                  |                  |                 |                  |     | 140 | 129              | 92%              |                  |
| --- Samples and groups ---      | [µmol/L] |               |    |        |                  |                  |                  |                 |                  |     |     |                  |                  |                  |
| <b>Sample A</b>                 |          | 367           | 25 | 6,8    | 140              | CVP              | 367              | 5,2             | 20%              | 293 | 441 | 140              | 130              | 93%              |
| (1) Jendrassik - Gróf           |          | 367           | 33 | 8,9    | 14               | 0                |                  |                 |                  |     |     | 14               |                  |                  |
| (2) DCA, DPD                    |          | 360           | 18 | 5,1    | 102              | 0                |                  |                 |                  |     |     | 102              |                  |                  |
| (7) Oxidation-reduction methods |          | 408           | 28 | 6,8    | 18               | 0                |                  |                 |                  |     |     | 18               |                  |                  |
| Other                           |          |               |    |        | 6                | 0                |                  |                 |                  |     |     | 6                |                  |                  |
|                                 |          |               |    |        |                  |                  | 4x 3, 1x 5, 1x 6 |                 |                  |     |     |                  |                  |                  |
| <b>Sample B</b>                 |          | 224           | 15 | 6,8    | 140              | CVP              | 224              | 3,1             | 20%              | 179 | 269 | 140              | 137              | 98%              |
| (1) Jendrassik - Gróf           |          | 230           | 15 | 6,4    | 14               | 0                |                  |                 |                  |     |     | 14               |                  |                  |
| (2) DCA, DPD                    |          | 221           | 14 | 6,3    | 102              | 0                |                  |                 |                  |     |     | 102              |                  |                  |
| (7) Oxidation-reduction methods |          | 239           | 16 | 6,5    | 18               | 0                |                  |                 |                  |     |     | 18               |                  |                  |
| Other                           |          |               |    |        | 6                | 0                |                  |                 |                  |     |     | 6                |                  |                  |
|                                 |          |               |    |        |                  |                  | 4x 3, 1x 5, 1x 6 |                 |                  |     |     |                  |                  |                  |

st\_kn\_p

End of report

Printed: 26.08.2020